8 completed, 1 terminated, 1 unknown. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 3 |
Follow LCL161: new trials by email Literature Review of LCL161 trials Research Report on LCL161
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma PDR001, CJM112, LCL161 - Multiple Myeloma | Phase 1 | Completed | Novartis Pharmaceuticals | 26 | 2017-12-18 | 2022-02-09 |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat PDR001, LCL161, Everolimus - Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma | Phase 1 | Completed | Novartis Pharmaceuticals | 298 | 2016-10-14 | 2023-01-11 |
| LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies LCL161, Topotecan, Pegylated GCSF (PEG-GCSF) - Small Cell Lung Cancer, Ovarian Cancer | Phase 1 | Terminated | SCRI Development Innovations, LLC | 34 | 2016-03-23 | 2023-12-05 |
| LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis Laboratory Biomarker Analysis, Questionnaire Administration, Smac Mimetic LCL161 - Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis | Phase 2 | Completed | M.D. Anderson Cancer Center | 50 | 2014-12-18 | 2023-06-06 |
| Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer LCL161, Gemcitabine, nab-Paclitaxel - Metastatic Pancreatic Cancer | Phase 1 | Unknown | US Oncology Research | 24 | 2014-03-01 | 2015-11-10 |
| Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors LCL161, Paclitaxel - Neoplasms | Phase 1 | Completed | Novartis Pharmaceuticals | 9 | 2013-11-01 | 2020-12-19 |
| SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma Cyclophosphamide, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Completed | Mayo Clinic | 25 | 2013-11-01 | 2019-09-10 |
| A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer LCL161, paclitaxel - Breast Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 209 | 2012-08-01 | 2016-10-17 |
| A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors LCL161, Paclitaxel - Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 76 | 2011-04-01 | 2020-12-19 |
| Safety and Efficacy of LCL161 in Patients With Solid Tumors LCL161 - Advanced Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 71 | 2008-11-01 | 2012-08-03 |
Multiple Myeloma (2) · Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Hematologic Diseases (1) · Lung Neoplasms (1) · Neoplasms, Plasma Cell (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1)
Novartis Pharmaceuticals (6) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · SCRI Development Innovations, LLC (1) · US Oncology Research (1)
United States (9) · Spain (4) · Germany (3) · Italy (3) · South Korea (2) · Taiwan (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Canada (1) · Czechia (1) · Ireland (1) · Japan (1) · Netherlands (1) · Russia (1)
Carlos H. Becerra, MD (1) · Melissa Johnson, MD (1) · Naveen Pemmaraju (1) · Peter Bergsagel (1) · Yvonne M. Coyle, MD (1)
PMID 25113756, PMID 34424319, PMID 37129455
2009 (1), P30CA015083 (1)